Answers are grounded in this paper and cite their sources.
Background Cancer stemness, characterised by SOX9 expression, drives therapeutic resistance and relapse in gastric cancer (GC), yet the mechanisms by which the tumour microenvironment (TME) regulates GC stemness remain poorly defined. Objective To compare regulatory networks associated with SOX9 expression in GC. Design We performed an integrative multi-omics analysis combining single-cell and spatial transcriptomics, bulk RNA sequencing, imaging mass cytometry and proteomics. Mechanistic validation was conducted using multiplex immunofluorescence, co-immunoprecipitation, xenograft models and fibroblast-specific Fosl1 conditional knockout (CKO) mice. Results We identified a novel subset of GPNMB+ cancer-associated fibroblasts (CAFs), which was enriched in SOX9high GC and correlated with poor prognosis, promoted stemness via IGF1-IGF1R signalling. CAF-derived IGF1 activated IGF1R on malignant cells, inducing SRCY419 and YAP1Y357 phosphorylation, which facilitated IGF1R-SRC-YAP1 complex formation and SOX9 expression. FOSL1 transcriptionally regulated GPNMB and IGF1 expression in CAFs. Reciprocally, IGF1-stimulated malignant cells secreted AREG, activating CAF-expressed EGFR signalling. EGFR-GPNMB synergy triggered NF-κB-mediated FOSL1 upregulation, reinforcing the GPNMB+ CAF phenotype and establishing a self-reinforcing cancer stem cell niche loop. Fibroblast-specific Fosl1 CKO suppressed GC growth and stemness. Targeting IGF1 or SRC sensitised tumours to chemotherapy in vivo. Conclusions Our findings unravel the pivotal role of GPNMB+ CAFs in driving GC stemness via the IGF1R-SRC-YAP1-SOX9 signalling axis. Disrupting this axis or its upstream regulator FOSL1 offers a therapeutic strategy to ablate TME-supported stemness and overcome chemoresistance.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: